Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study
Abstract Background Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA) with glycopeptides is inferior compared to treatment with β-lactam. However, there are only few studies comparing treatment with antistaphylococcal penicillin alone to glycopeptide...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-01-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12879-018-2978-z |
| _version_ | 1818296893954850816 |
|---|---|
| author | Dong Hyun Oh Jung Ju Kim Jinnam Kim Hye Seong Se Ju Lee Yong Chan Kim Eun Jin Kim In Young Jung Woo Yong Jeong Su Jin Jeong Nam Su Ku Sang Hoon Han Jun Yong Choi Young Goo Song June Myung Kim |
| author_facet | Dong Hyun Oh Jung Ju Kim Jinnam Kim Hye Seong Se Ju Lee Yong Chan Kim Eun Jin Kim In Young Jung Woo Yong Jeong Su Jin Jeong Nam Su Ku Sang Hoon Han Jun Yong Choi Young Goo Song June Myung Kim |
| author_sort | Dong Hyun Oh |
| collection | DOAJ |
| description | Abstract Background Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA) with glycopeptides is inferior compared to treatment with β-lactam. However, there are only few studies comparing treatment with antistaphylococcal penicillin alone to glycopeptide treatment. The aim of this study was to compare the efficacy of nafcillin, an antistaphylococcal penicillin, with that of glycopeptides as a definitive therapy for MSSA bacteremia. Methods Patients with MSSA bacteremia recruited from a tertiary referral hospital were enrolled in this retrospective cohort study. Demographic characteristics, laboratory data, and clinical outcome of the treatment were compared between a group receiving nafcillin and a group receiving glycopeptides. Results A total of 188 patients with MSSA bacteremia were included in this study. The glycopeptide group had a higher rate of malignancy (28.6 vs. 60.8%, p < 0.001) and proportion of healthcare-associated infections (47.3 vs. 72.2%, p < 0.001) compared to the nafcillin group. The ratio of skin and soft tissue infections (30.0 vs. 16.7%, p = 0.037) and bone and joint infections (17.8 vs. 6.3%, p = 0.022), as well as levels of C-reactive protein (139.60 vs. 107.61 mg/dL, p = 0.022) were higher in the nafcillin group. All-cause 28-day mortality was significantly high in the glycopeptide group (7.7 vs. 20.6%, p = 0.013). Conclusion In patients with MSSA bacteremia, all-cause 28-day mortality rate was higher in a group treated with glycopeptides than in a group treated with nafcillin. Therefore, the use of nafcillin should be considered as a definitive therapy for MSSA bacteremia. |
| first_indexed | 2024-12-13T04:10:47Z |
| format | Article |
| id | doaj.art-6b31798433154897a6dd782211bf970c |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-12-13T04:10:47Z |
| publishDate | 2018-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-6b31798433154897a6dd782211bf970c2022-12-22T00:00:05ZengBMCBMC Infectious Diseases1471-23342018-01-011811710.1186/s12879-018-2978-zComparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort studyDong Hyun Oh0Jung Ju Kim1Jinnam Kim2Hye Seong3Se Ju Lee4Yong Chan Kim5Eun Jin Kim6In Young Jung7Woo Yong Jeong8Su Jin Jeong9Nam Su Ku10Sang Hoon Han11Jun Yong Choi12Young Goo Song13June Myung Kim14Department of Internal Medicine, Seoul Medical CenterDepartment of Internal Medicine, Yonsei University College of MedicineDepartment of Internal Medicine, Yonsei University College of MedicineDepartment of Internal Medicine, Yonsei University College of MedicineDepartment of Internal Medicine, Yonsei University College of MedicineDepartment of Internal Medicine, Yonsei University College of MedicineDepartment of Internal Medicine, Yonsei University College of MedicineDepartment of Internal Medicine, Yonsei University College of MedicineDepartment of Internal Medicine, Yonsei University College of MedicineDepartment of Internal Medicine, Yonsei University College of MedicineDepartment of Internal Medicine, Yonsei University College of MedicineDepartment of Internal Medicine, Yonsei University College of MedicineDepartment of Internal Medicine, Yonsei University College of MedicineDepartment of Internal Medicine, Yonsei University College of MedicineDepartment of Internal Medicine, Yonsei University College of MedicineAbstract Background Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA) with glycopeptides is inferior compared to treatment with β-lactam. However, there are only few studies comparing treatment with antistaphylococcal penicillin alone to glycopeptide treatment. The aim of this study was to compare the efficacy of nafcillin, an antistaphylococcal penicillin, with that of glycopeptides as a definitive therapy for MSSA bacteremia. Methods Patients with MSSA bacteremia recruited from a tertiary referral hospital were enrolled in this retrospective cohort study. Demographic characteristics, laboratory data, and clinical outcome of the treatment were compared between a group receiving nafcillin and a group receiving glycopeptides. Results A total of 188 patients with MSSA bacteremia were included in this study. The glycopeptide group had a higher rate of malignancy (28.6 vs. 60.8%, p < 0.001) and proportion of healthcare-associated infections (47.3 vs. 72.2%, p < 0.001) compared to the nafcillin group. The ratio of skin and soft tissue infections (30.0 vs. 16.7%, p = 0.037) and bone and joint infections (17.8 vs. 6.3%, p = 0.022), as well as levels of C-reactive protein (139.60 vs. 107.61 mg/dL, p = 0.022) were higher in the nafcillin group. All-cause 28-day mortality was significantly high in the glycopeptide group (7.7 vs. 20.6%, p = 0.013). Conclusion In patients with MSSA bacteremia, all-cause 28-day mortality rate was higher in a group treated with glycopeptides than in a group treated with nafcillin. Therefore, the use of nafcillin should be considered as a definitive therapy for MSSA bacteremia.http://link.springer.com/article/10.1186/s12879-018-2978-zMethicillin-susceptible Staphylococcus aureusNafcillinAntistaphylococcal penicillinGlycopeptides |
| spellingShingle | Dong Hyun Oh Jung Ju Kim Jinnam Kim Hye Seong Se Ju Lee Yong Chan Kim Eun Jin Kim In Young Jung Woo Yong Jeong Su Jin Jeong Nam Su Ku Sang Hoon Han Jun Yong Choi Young Goo Song June Myung Kim Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study BMC Infectious Diseases Methicillin-susceptible Staphylococcus aureus Nafcillin Antistaphylococcal penicillin Glycopeptides |
| title | Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study |
| title_full | Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study |
| title_fullStr | Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study |
| title_full_unstemmed | Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study |
| title_short | Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study |
| title_sort | comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin susceptible staphylococcus aureus bacteremia a retrospective cohort study |
| topic | Methicillin-susceptible Staphylococcus aureus Nafcillin Antistaphylococcal penicillin Glycopeptides |
| url | http://link.springer.com/article/10.1186/s12879-018-2978-z |
| work_keys_str_mv | AT donghyunoh comparisonoftheefficacyofnafcillinandglycopeptidesasdefinitivetherapyforpatientswithmethicillinsusceptiblestaphylococcusaureusbacteremiaaretrospectivecohortstudy AT jungjukim comparisonoftheefficacyofnafcillinandglycopeptidesasdefinitivetherapyforpatientswithmethicillinsusceptiblestaphylococcusaureusbacteremiaaretrospectivecohortstudy AT jinnamkim comparisonoftheefficacyofnafcillinandglycopeptidesasdefinitivetherapyforpatientswithmethicillinsusceptiblestaphylococcusaureusbacteremiaaretrospectivecohortstudy AT hyeseong comparisonoftheefficacyofnafcillinandglycopeptidesasdefinitivetherapyforpatientswithmethicillinsusceptiblestaphylococcusaureusbacteremiaaretrospectivecohortstudy AT sejulee comparisonoftheefficacyofnafcillinandglycopeptidesasdefinitivetherapyforpatientswithmethicillinsusceptiblestaphylococcusaureusbacteremiaaretrospectivecohortstudy AT yongchankim comparisonoftheefficacyofnafcillinandglycopeptidesasdefinitivetherapyforpatientswithmethicillinsusceptiblestaphylococcusaureusbacteremiaaretrospectivecohortstudy AT eunjinkim comparisonoftheefficacyofnafcillinandglycopeptidesasdefinitivetherapyforpatientswithmethicillinsusceptiblestaphylococcusaureusbacteremiaaretrospectivecohortstudy AT inyoungjung comparisonoftheefficacyofnafcillinandglycopeptidesasdefinitivetherapyforpatientswithmethicillinsusceptiblestaphylococcusaureusbacteremiaaretrospectivecohortstudy AT wooyongjeong comparisonoftheefficacyofnafcillinandglycopeptidesasdefinitivetherapyforpatientswithmethicillinsusceptiblestaphylococcusaureusbacteremiaaretrospectivecohortstudy AT sujinjeong comparisonoftheefficacyofnafcillinandglycopeptidesasdefinitivetherapyforpatientswithmethicillinsusceptiblestaphylococcusaureusbacteremiaaretrospectivecohortstudy AT namsuku comparisonoftheefficacyofnafcillinandglycopeptidesasdefinitivetherapyforpatientswithmethicillinsusceptiblestaphylococcusaureusbacteremiaaretrospectivecohortstudy AT sanghoonhan comparisonoftheefficacyofnafcillinandglycopeptidesasdefinitivetherapyforpatientswithmethicillinsusceptiblestaphylococcusaureusbacteremiaaretrospectivecohortstudy AT junyongchoi comparisonoftheefficacyofnafcillinandglycopeptidesasdefinitivetherapyforpatientswithmethicillinsusceptiblestaphylococcusaureusbacteremiaaretrospectivecohortstudy AT younggoosong comparisonoftheefficacyofnafcillinandglycopeptidesasdefinitivetherapyforpatientswithmethicillinsusceptiblestaphylococcusaureusbacteremiaaretrospectivecohortstudy AT junemyungkim comparisonoftheefficacyofnafcillinandglycopeptidesasdefinitivetherapyforpatientswithmethicillinsusceptiblestaphylococcusaureusbacteremiaaretrospectivecohortstudy |